var title_f4_61_5072="TEE left atrial appendage thrombus and spontaneous echo contrast";
var content_f4_61_5072=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/66795/teethla2_conv.mp4?title=TEE+left+atrial+appendage+thrombus+and+spontaneous+echo+contrast+\" style=\"width:312px;height:224px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transesophageal echocardiography (TEE) showing left atrial appendage thrombus and spontaneous echo contrast",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 267px; height: 207px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transesophageal echocardiogram shows a large mobile thrombus in the left atrial appendage, extending into the body of the left atrium. Spontaneous echo contrast can be seen in the left atrium.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_61_5072=[""].join("\n");
var outline_f4_61_5072=null;
var title_f4_61_5073="Garden type IV hip fracture";
var content_f4_61_5073=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F59095&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F59095&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Garden type IV hip fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 374px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In the Garden type IV fracture, there is complete displacement between fragments and the shaft translates proximally. The head is free to realign itself within the acetabulum, and the primary compressive trabeculae of the head and acetabulum realign (white lines).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Baumgaertner MR, Higgins TF. Femoral neck fractures. In: Rockwood and Green's Fractures in Adults, 5th ed,&nbsp;Bucholz RW, Heckman JD (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2002. Copyright &copy; 2002 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_61_5073=[""].join("\n");
var outline_f4_61_5073=null;
var title_f4_61_5074="Distal radioulnar joint compression test";
var content_f4_61_5074=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F78662&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F78662&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Distal radioulnar joint (DRUJ) compression test for DRUJ instability",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 430px; height: 437px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    To perform the DRUJ compression test, the examiner compresses the radial and ulnar heads together and then rotates the forearm. Pain with the maneuver suggests DRUJ instability, acute intraarticular injury, or arthritis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_61_5074=[""].join("\n");
var outline_f4_61_5074=null;
var title_f4_61_5075="Dermatitis herpetiformis knees PI";
var content_f4_61_5075=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F87426&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F87426&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Dermatitis herpetiformis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 377px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The rash of dermatitis herpetiformis often appears on the knees, elbows, forearms or buttocks. The bumps or blisters are itchy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_61_5075=[""].join("\n");
var outline_f4_61_5075=null;
var title_f4_61_5076="Vaccinia immune globulin (intravenous): Patient drug information";
var content_f4_61_5076=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Vaccinia immune globulin (intravenous): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/33/6677?source=see_link\">",
"     see \"Vaccinia immune globulin (intravenous): Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F786671\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      CNJ-016&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10026283\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705920",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor about which glucose tests are best to use.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10026285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705830",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat side effects caused by smallpox vaccine.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10026284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703109",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to vaccinia immune globulin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703771",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have IgA deficiency.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10026289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10026290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698088",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Allergic side effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10026292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10026287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10026293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10026294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12149 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-122.72.76.133-CAE5397922-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_61_5076=[""].join("\n");
var outline_f4_61_5076=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786671\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026283\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026285\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026284\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026289\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026290\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026292\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026287\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026293\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026294\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?6/33/6677?source=related_link\">",
"      Vaccinia immune globulin (intravenous): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_61_5077="Lentigo maligna staged excision";
var content_f4_61_5077=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F71333&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F71333&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Staged excision of lentigo maligna",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 550px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_61_5077=[""].join("\n");
var outline_f4_61_5077=null;
var title_f4_61_5078="Fexofenadine and pseudoephedrine: Drug information";
var content_f4_61_5078=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fexofenadine and pseudoephedrine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?21/63/22517?source=see_link\">",
"    see \"Fexofenadine and pseudoephedrine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F171136\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Allegra-D&reg; 12 Hour;",
"     </li>",
"     <li>",
"      Allegra-D&reg; 24 Hour",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F171137\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Allegra-D&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F171152\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Alpha-/Beta- Agonist;",
"     </li>",
"     <li>",
"      Decongestant;",
"     </li>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist",
"     </li>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist, Second Generation",
"     </li>",
"     <li>",
"      Piperidine Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F171138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Allergic symptoms and nasal congestion: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Allegra-D&reg; 12 Hour: One tablet twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Allegra-D&reg; 24 Hour: One tablet once daily",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F171147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F171139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F171140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Allegra-D&reg; 12 Hour: Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;80 mL/minute (based on fexofenadine component): One tablet once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Allegra-D&reg; 24 Hour: Avoid use.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15881422\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; however, need for adjustment not likely since fexofenadine undergoes minimal hepatic metabolism; impact of hepatic impairment on pseudoephedrine pharmacokinetics are unknown.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F171125\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, extended release: Fexofenadine hydrochloride 60 mg [immediate release] and pseudoephedrine hydrochloride 120 mg [extended release]; fexofenadine hydrochloride 180 mg [immediate release] and pseudoephedrine hydrochloride 240 mg [extended release]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Allegra-D&reg; 12 Hour: Fexofenadine hydrochloride 60 mg [immediate release] and pseudoephedrine hydrochloride 120 mg [extended release]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Allegra-D&reg; 24 Hour: Fexofenadine hydrochloride 180 mg [immediate release] and pseudoephedrine hydrochloride 240 mg [extended release]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F171114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F171128\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tablets should be swallowed whole; do not crush or chew. Administer on an empty stomach with water; avoid administration with food. The inactive ingredients may be eliminated in the feces in a form resembling the original tablet.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F171127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of symptoms associated with seasonal allergic rhinitis in adults and children &ge;12 years of age",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F171158\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Allegra-D&reg; may be confused with Viagra&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Allegra-D [U.S, Canada, and multiple international markets] may be confused with Allegro brand name for fluticasone [Israel] and frovatriptan [Germany]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F171150\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F171131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to fexofenadine, pseudoephedrine, or any component of the formulation; narrow-angle glaucoma; urinary retention; during or within 14 days of MAO inhibitor therapy; severe hypertension or coronary heart disease",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F171117\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (including hypertension and ischemic heart disease); contraindicated with severe disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Increased intraocular pressure: Use with caution in patients with increased intraocular pressure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia/urinary obstruction: Use with caution in patients with prostatic hyperplasia and/or GU obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorder: Use with caution in patients with seizure disorder; may produce CNS stimulation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F171148\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F171121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May diminish the hypertensive effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May diminish the sedative effect of Antihistamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of Fexofenadine. Management: No specific recommendations concerning the time required between their administration are provided. Separate administration of each agent by as much time as possible to decrease the risk of an interaction.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Calcium Carbonate; Magaldrate; Sodium Bicarbonate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Aluminum Hydroxide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Alpha-/Beta-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bromocriptine: Alpha-/Beta-Agonists may enhance the adverse/toxic effect of Bromocriptine. Including increased blood pressure, ventricular arrhythmias, and seizure.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: May increase the serum concentration of OATP1B1/SLCO1B1 Substrates. Management: According to eltrombopag prescribing information, consideration of a preventative dose reduction may be warranted.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the hypertensive effect of Alpha-/Beta-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erythromycin (Systemic): May increase the serum concentration of Fexofenadine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: Alpha-/Beta-Agonists (Indirect-Acting) may decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May decrease the serum concentration of Fexofenadine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: May increase the serum concentration of Fexofenadine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): May increase the serum concentration of Fexofenadine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Alpha-/Beta-Agonists (Indirect-Acting).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May decrease the serum concentration of Fexofenadine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the tachycardic effect of Alpha-/Beta-Agonists. Serotonin/Norepinephrine Reuptake Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Spironolactone: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Verapamil: May increase the bioavailability of Fexofenadine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F10204064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Food: High-fat meals decrease the bioavailability of fexofenadine by ~50%. Fruit juices (eg apple, grapefruit, orange) may decrease the bioavailability of fexofenadine by 36%.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F171122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F171132\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies using this combination showed reduced fetal weight, delayed ossification, and decreased survival. Also refer to individual monographs.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F171143\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution (AAP rates \"compatible\"; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F171133\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pseudoephedrine is excreted in breast milk; excretion of fexofenadine is not known. Also refer to individual monographs.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F10204010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Doses should be administered on an empty stomach with water.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F2524574\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 12-hour",
"     </b>",
"     (Allegra-D Allergy &amp; Congestion Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60-120 mg (10): $11.88",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Allegra-D Allergy &amp; Congestion Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     180-240 mg (5): $7.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Fexofenadine-Pseudoephed ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     180-240 mg (10): $8.75",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F171134\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Alerfedine D (AR);",
"     </li>",
"     <li>",
"      Allegra-D (BB, BM, BR, BS, BZ, CN, CO, CR, DO, EC, GT, GY, HN, JM, KP, MX, NI, NL, PA, PE, PR, PY, SR, SV, TT, UY, VE);",
"     </li>",
"     <li>",
"      Fexofed (ID);",
"     </li>",
"     <li>",
"      Rinolast D (CO);",
"     </li>",
"     <li>",
"      Telfast (PH);",
"     </li>",
"     <li>",
"      Telfast BD 60 (ID);",
"     </li>",
"     <li>",
"      Telfast Decongestant (AU);",
"     </li>",
"     <li>",
"      Telfast HD 180 (ID);",
"     </li>",
"     <li>",
"      Telfast OD 120 (ID);",
"     </li>",
"     <li>",
"      Telfast Plus (ID);",
"     </li>",
"     <li>",
"      Telfast-D (HK, MY, SG, TH);",
"     </li>",
"     <li>",
"      Telfex-d (PK)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F171130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/61/5078/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8746 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-3636CB1C0C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_61_5078=[""].join("\n");
var outline_f4_61_5078=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171136\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171137\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171152\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171138\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171147\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171139\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171140\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15881422\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171125\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171114\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171128\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171127\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171158\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171150\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171131\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171117\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171148\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171121\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10204064\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171122\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171132\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171143\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171133\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10204010\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2524574\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171134\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171130\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8746\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8746|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?21/63/22517?source=related_link\">",
"      Fexofenadine and pseudoephedrine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_61_5079="Definition standard drink";
var content_f4_61_5079=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F68118&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F68118&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Definition of a \"standard drink\"",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 446px; height: 758px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Note: Depending on factors such as the type of spirits and the recipe, one mixed drink can contain from one to three or more standard drinks.",
"    </div>",
"    <div class=\"reference\">",
"     National Institute on Alcohol Abuse and Alcoholism - file://pubs.niaaa.nih.gov/publications/Practitioner/pocketguide/pocket_guide2.htm.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_61_5079=[""].join("\n");
var outline_f4_61_5079=null;
var title_f4_61_5080="Type III hereditary angioedema";
var content_f4_61_5080=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Type III hereditary angioedema",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/61/5080/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/61/5080/contributors\">",
"     Eveline Wu, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/61/5080/contributors\">",
"     Michael M Frank, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/61/5080/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/61/5080/contributors\">",
"     Sarbjit Saini, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/61/5080/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/61/5080/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/61/5080/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H6433169\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary angioedema (HAE) is characterized by recurrent, self-limited episodes of swelling primarily involving the skin and the mucosa of the gastrointestinal tract and upper airway. Three types of HAE have been distinguished. The clinical manifestations, pathogenesis, diagnosis, and management of type III HAE will be reviewed here.",
"   </p>",
"   <p>",
"    HAE types I and II are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19272?source=see_link\">",
"       \"Hereditary angioedema: Epidemiology, clinical manifestations, exacerbating factors, and prognosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33864?source=see_link\">",
"       \"Hereditary angioedema: Pathogenesis and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/61/29658?source=see_link\">",
"       \"Hereditary angioedema: Prevention of attacks\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33657?source=see_link\">",
"       \"Hereditary angioedema: Treatment of acute attacks\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6433176\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Information about the incidence and prevalence of type III HAE is limited because it is a rare and newly-described disorder. HAE type III was initially assumed to be specific to women, but male members of affected families have since been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?4/61/5080/abstract/1\">",
"     1",
"    </a>",
"    ]. In the largest single series, approximately 8 percent of patients were male [",
"    <a class=\"abstract\" href=\"UTD.htm?4/61/5080/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10208171\">",
"    <span class=\"h1\">",
"     BACKGROUND AND TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, hereditary angioedema was described as a familial disorder resulting from either deficiency or dysfunction of the inhibitor of complement component 1 (C1 inhibitor or C1 INH). However, in 2000, two different groups published descriptions of another familial form of angioedema, in which affected individuals had normal C1 INH levels and activity [",
"    <a class=\"abstract\" href=\"UTD.htm?4/61/5080/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thirty-six people from 10 families were detailed in the earliest study [",
"      <a class=\"abstract\" href=\"UTD.htm?4/61/5080/abstract/3\">",
"       3",
"      </a>",
"      ]. All of the affected individuals were women and all of those tested had normal C1 INH function and plasma concentration.",
"     </li>",
"     <li>",
"      In a second report published in the same year, seven women from a single family were described, in whom episodes only occurred during pregnancy or with the use of exogenous estrogens [",
"      <a class=\"abstract\" href=\"UTD.htm?4/61/5080/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Subsequently, a number of additional families were described [",
"    <a class=\"abstract\" href=\"UTD.htm?4/61/5080/abstract/2,5,6\">",
"     2,5,6",
"    </a>",
"    ]. The largest series included 138 patients from 43 families [",
"    <a class=\"abstract\" href=\"UTD.htm?4/61/5080/abstract/2\">",
"     2",
"    </a>",
"    ]. The terms \"estrogen-dependent&rdquo; and &ldquo;estrogen-associated inherited angioedema\" were used to describe this disorder prior to the identification of male patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/61/5080/abstract/7\">",
"     7",
"    </a>",
"    ]. Because the pathogenesis has not been fully determined, this new form of HAE has been designated HAE type III or HAE with normal C1 inhibitor. Terminology will likely evolve as the pathogenesis of the disease is revealed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6433307\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;HAE type III has signs and symptoms similar to those of types I and II, with some distinguishing features.",
"   </p>",
"   <p>",
"    Similarities between the three disorders include the occurrence of self-limited episodes of subcutaneous and submucosal angioedema lasting two to five days in the absence of treatment. All disorders affect the skin and the mucosa of the gastrointestinal and upper respiratory tract. Cutaneous attacks are the most common type, and episodes affecting the upper airway are less common but potentially life-threatening in all three disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?4/61/5080/abstract/2,8\">",
"     2,8",
"    </a>",
"    ]. Affected skin is nonpruritic and nonpitting and urticaria is not seen. Some patients report a prodrome of numbness or tingling at the affected site. There is significant heterogeneity in all three disorders; members of an affected family may be asymptomatic or symptomatic to varying degrees [",
"    <a class=\"abstract\" href=\"UTD.htm?4/61/5080/abstract/2,9\">",
"     2,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations of HAE are presented in more detail elsewhere. The remainder of the discussion here will focus on the differences between type III and the other forms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19272?source=see_link\">",
"     \"Hereditary angioedema: Epidemiology, clinical manifestations, exacerbating factors, and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6791385\">",
"    <span class=\"h2\">",
"     Unique characteristics of type III",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some differences have been noted between type III and types I and II:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Age of onset",
"      </strong>",
"      : Type III HAE usually presents in adulthood (after puberty). In the largest series of 138 patients with type III HAE, the mean age at disease onset was 26.8 years [",
"      <a class=\"abstract\" href=\"UTD.htm?4/61/5080/abstract/2\">",
"       2",
"      </a>",
"      ]. In contrast, more than one-half of patients with types I and II HAE present during childhood [",
"      <a class=\"abstract\" href=\"UTD.htm?4/61/5080/abstract/2,8\">",
"       2,8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       More prominent involvement of the tongue, uvula, and face",
"      </strong>",
"      : In type III HAE, angioedema of the tongue, uvula, and facial skin occurs with higher frequency, and tongue swelling may be a diagnostic clue to the presence of type III HAE [",
"      <a class=\"abstract\" href=\"UTD.htm?4/61/5080/abstract/2,10\">",
"       2,10",
"      </a>",
"      ]. In the series of 138 patients mentioned previously, 54 percent experienced tongue swelling, compared to 12 percent in a series of patients with HAE types I and II [",
"      <a class=\"abstract\" href=\"UTD.htm?4/61/5080/abstract/2\">",
"       2",
"      </a>",
"      ]. Tongue swelling may herald laryngeal edema. Among 35 patients with laryngeal edema, 13 had experienced episodes associated with tongue swellings [",
"      <a class=\"abstract\" href=\"UTD.htm?4/61/5080/abstract/2\">",
"       2",
"      </a>",
"      ]. Four of 138 patients in this series died due to asphyxiation.",
"     </li>",
"     <li>",
"      <strong>",
"       Less frequent abdominal attacks",
"      </strong>",
"      : Approximately 50 percent of type III patients experience abdominal attacks, compared with at least 90 percent in patients with types I and II [",
"      <a class=\"abstract\" href=\"UTD.htm?4/61/5080/abstract/2,8,10,11\">",
"       2,8,10,11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Females are affected more often and more severely",
"      </strong>",
"      : Within families affected by type III HAE, females are more often symptomatic and have more severe symptoms than males [",
"      <a class=\"abstract\" href=\"UTD.htm?4/61/5080/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Less intense and more variable disease activity:",
"      </strong>",
"      Patients with type III HAE demonstrate a decreased frequency of symptoms and a greater number of disease-free intervals. Many patients with HAE type III experience prolonged periods (ie, one to several years) without symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?4/61/5080/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Different cutaneous findings",
"      </strong>",
"      : Hemorrhages into skin swellings and easy bruising have been reported in several patients with HAE type III, although not in patients with types I and II [",
"      <a class=\"abstract\" href=\"UTD.htm?4/61/5080/abstract/2\">",
"       2",
"      </a>",
"      ]. The prodromal skin discoloration, erythema marginatum, which is reported by up to one-third of patients with HAE types I and II, has",
"      <strong>",
"       not",
"      </strong>",
"      been observed in HAE type III (",
"      <a class=\"graphic graphic_picture graphicRef79093 \" href=\"UTD.htm?26/15/26879\">",
"       picture 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6433183\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mediator(s) responsible for swelling in type III HAE has not been identified. Excess generation of bradykinin, a potent vasoactive substance, has convincingly been shown to be the major facilitator of angioedema in HAE types I and II [",
"    <a class=\"abstract\" href=\"UTD.htm?4/61/5080/abstract/12\">",
"     12",
"    </a>",
"    ]. Activation of the kinin system may also be critical to type III HAE, but this has not been conclusively demonstrated.",
"   </p>",
"   <p>",
"    The underlying molecular defect(s) for most patients with type III HAE has not been determined, although the pattern of affected family members in successive generations supports an autosomal dominant mode of inheritance [",
"    <a class=\"abstract\" href=\"UTD.htm?4/61/5080/abstract/2,4,5\">",
"     2,4,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6433190\">",
"    <span class=\"h2\">",
"     Mutations in the FXII gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the importance of excess bradykinin formation in types I and II HAE, it is reasonable to speculate that mutations of elements in the kinin-generating cascade may be responsible for HAE type III, as well. The kinin-generating pathways interface with the coagulation (contact system) and fibrinolytic pathways (",
"    <a class=\"graphic graphic_figure graphicRef87451 \" href=\"UTD.htm?40/51/41791\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Several mutations in the coagulation factor XII (FXII, Hageman factor) gene have been identified in patients with type III HAE living in Europe:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two missense mutations involving the factor XII gene were detected among six index patients from 20 unrelated families [",
"      <a class=\"abstract\" href=\"UTD.htm?4/61/5080/abstract/13\">",
"       13",
"      </a>",
"      ]. Both mutations were single heterozygous nucleotide substitutions within exon 9 of the FXII gene. The first and most common point mutation c.983C&gt;A (old nomenclature: c.1032C&gt;A, Thr309Lys) results in substitution of a threonine residue for lysine (Thr328Lys), and the second c.983C&gt;G (old nomenclature: c.1032C&gt;G, Thr309Arg) results in substitution of the same threonine residue for arginine (Thr328Arg) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/61/5080/abstract/13,14\">",
"       13,14",
"      </a>",
"      ]. Neither mutation was detectable in 145 healthy controls. The same mutations have subsequently been identified in multiple other affected families [",
"      <a class=\"abstract\" href=\"UTD.htm?4/61/5080/abstract/15-21\">",
"       15-21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A different FXII gene mutation resulting in deletion of a considerable number of base pairs (c.971_1018+24del72*) was identified in another family [",
"      <a class=\"abstract\" href=\"UTD.htm?4/61/5080/abstract/14\">",
"       14",
"      </a>",
"      ]. This large deletion is located in the same gene region as the previously identified missense mutations and was not detected in a large number of control subjects.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The observation that several different mutations involving the same FXII gene region are present in affected patients and not in controls supports an association between FXII protein modifications and HAE type III [",
"    <a class=\"abstract\" href=\"UTD.htm?4/61/5080/abstract/22\">",
"     22",
"    </a>",
"    ]. However, the mechanism by which defective factor XII would lead to increased formation of bradykinin has not been demonstrated. Specifically, in one study, mutations in the FXII gene were associated with normal plasma concentrations of FXII but an increase in its enzymatic activity when compared to healthy controls [",
"    <a class=\"abstract\" href=\"UTD.htm?4/61/5080/abstract/15\">",
"     15",
"    </a>",
"    ]. However, these findings could not be reproduced in a follow-up study using a more sensitive assay, and functional defects in FXII were not found [",
"    <a class=\"abstract\" href=\"UTD.htm?4/61/5080/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Not all members of a given family who carry the FXII mutations are symptomatic, indicating that penetrance must be incomplete and other factors are necessary for disease development.",
"   </p>",
"   <p>",
"    Factor XII mutations do not appear to be equally prevalent in all populations. In the large German series of 138 patients, 23 (17 percent) demonstrated one of the two identified FXII mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?4/61/5080/abstract/2\">",
"     2",
"    </a>",
"    ]. In another series by the same group, one of these mutations was present in 25 percent of the families tested [",
"    <a class=\"abstract\" href=\"UTD.htm?4/61/5080/abstract/9\">",
"     9",
"    </a>",
"    ]. However, neither of these mutations was found in 40 patients analyzed in the United States, although the study in which this was reported was an analysis of samples submitted to a speciality commercial laboratory, and the clinical features of the patients were not available to the researchers [",
"    <a class=\"abstract\" href=\"UTD.htm?4/61/5080/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6433197\">",
"    <span class=\"h2\">",
"     Other genetic mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polymorphisms in the genes encoding aminopeptidase P and angiotensin converting enzyme (ACE), two enzymes that degrade bradykinin, were reported in three female subjects with HAE type III. However, these patients also possessed the Thr328Lys mutation in the FXII gene [",
"    <a class=\"abstract\" href=\"UTD.htm?4/61/5080/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6433204\">",
"    <span class=\"h2\">",
"     Role of estrogens",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effects of estrogens in HAE type III is highly variable. Estrogens&rsquo; adverse effect on female patients with HAE type III was first highlighted in one of the original descriptions of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/61/5080/abstract/4\">",
"     4",
"    </a>",
"    ]. In this study, women only experienced angioedema attacks during pregnancy or while using some form of exogenous estrogen, including oral contraceptives and hormone replacement therapy. Additional patients with estrogen-exacerbated angioedema have since been described [",
"    <a class=\"abstract\" href=\"UTD.htm?4/61/5080/abstract/6,26,27\">",
"     6,26,27",
"    </a>",
"    ]. However, other women with type III HAE can tolerate high levels of estrogen without a worsening of angioedema attacks [",
"    <a class=\"abstract\" href=\"UTD.htm?4/61/5080/abstract/6,22\">",
"     6,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is not entirely clear how estrogens would induce attacks, although they may influence expression of factors important in the synthesis and degradation of bradykinin. High levels of estrogens may reduce plasma C1 INH levels, increase transcription of FXII protein, and increase plasma prekallikrein levels, all favoring an increase in bradykinin production (",
"    <a class=\"graphic graphic_figure graphicRef87451 \" href=\"UTD.htm?40/51/41791\">",
"     figure 1",
"    </a>",
"    ). ACE is important in degradation of bradykinin and its metabolite, and estrogens may reduce expression of ACE and allow bradykinin accumulation. Estrogens may also increase the expression of bradykinin type 2 receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?4/61/5080/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The negative influence of estrogens is not specific to type III HAE, since estrogen is a well-established trigger in some females with types I and II HAE. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19272?source=see_link&amp;anchor=H19#H19\">",
"     \"Hereditary angioedema: Epidemiology, clinical manifestations, exacerbating factors, and prognosis\", section on 'Triggers and exacerbating factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6433218\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of type III HAE is based on characteristic clinical features, a family history of angioedema, and normal complement studies. HAE should be suspected in a patient with recurrent, self-limited angioedema without urticaria, recurrent episodes of abdominal pain, laryngeal edema, and a family history of angioedema. Clinical features that help differentiate type III from types I and II HAE were reviewed previously. (See",
"    <a class=\"local\" href=\"#H6791385\">",
"     'Unique characteristics of type III'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A diagnostic algorithm has been established for evaluating such patients (",
"    <a class=\"graphic graphic_algorithm graphicRef64553 \" href=\"UTD.htm?1/50/1825\">",
"     algorithm 1",
"    </a>",
"    ). In contrast to those patients with either HAE type I or II, patients with HAE type III have normal C1 INH levels and activity, as well as normal C4 concentrations (",
"    <a class=\"graphic graphic_table graphicRef83098 \" href=\"UTD.htm?21/58/22444\">",
"     table 1",
"    </a>",
"    ). Complement studies should be obtained during symptoms on at least one occasion to confirm that they are normal even during an episode of angioedema. Because there is no specific confirmatory test for type III, it is generally accepted that a family history of angioedema is required for diagnosis, with the understanding that sporadic cases probably also exist. Thus, the following elements are necessary to make the diagnosis of type III HAE:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Episodic angioedema affecting characteristic organs, without urticaria",
"     </li>",
"     <li>",
"      A family history of angioedema",
"      <strong>",
"       OR",
"      </strong>",
"      the presence of one of the two described FXII mutations (see",
"      <a class=\"local\" href=\"#H6433190\">",
"       'Mutations in the FXII gene'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Normal C4",
"     </li>",
"     <li>",
"      Normal C1 inhibitor level. If C4 and C1 inhibitor levels are both normal, it is not necessary to measure C1 inhibitor function.",
"     </li>",
"     <li>",
"      No medications that could cause angioedema, such as ACE inhibitors or nonsteroidal antiinflammatory drugs (NSAIDs).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10254556\">",
"    <span class=\"h2\">",
"     Exclude idiopathic angioedema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idiopathic angioedema is a diagnosis of exclusion that describes recurrent episodes of angioedema without urticaria, for which no explanation can be found after a thorough evaluation to exclude drug reactions and allergic disorders (if indicated by the clinical history). Complement studies are normal in idiopathic angioedema. However, unlike type III HAE, idiopathic angioedema often improves with antihistamines, alone, or in combination with glucocorticoids. Therefore, a trial of antihistamine therapy is considered by several experts to be an important diagnostic step. The evidence supporting the use of H1 antihistamines in idiopathic angioedema is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/17/15641?source=see_link&amp;anchor=H32#H32\">",
"     \"An overview of angioedema: Clinical features, diagnosis, and management\", section on 'Recurrent, idiopathic angioedema'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following represents our approach, which has not been formally studied:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We treat patients with a nonsedating H1 antihistamine for at least one month (or an appropriate amount of time, depending upon the patient&rsquo;s frequency of symptoms). Options include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36390?source=see_link\">",
"       cetirizine",
"      </a>",
"      (10 mg daily),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/39/7799?source=see_link\">",
"       loratadine",
"      </a>",
"      (10 mg daily),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/33/35350?source=see_link\">",
"       fexofenadine",
"      </a>",
"      (180 mg daily), or a similar agent. If this does not prevent episodes of angioedema, we double the dose for another one to three months.",
"     </li>",
"     <li>",
"      In addition, we instruct patients to treat with additional medications at the first sign of symptoms. Some patients have identifiable sensations in the skin or tissue just before the onset of angioedema, and the medications should be taken when these sensations appear. In this setting, we ask patients to self administer 40 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      and 25 to 50 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"       diphenhydramine",
"      </a>",
"      , all at once, at the first sign of swelling, with no further doses.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If one or both of these measures prevents further episodes of angioedema, then the most appropriate diagnosis is idiopathic angioedema. Patients with type III HAE are not responsive to these therapies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1657995\">",
"    <span class=\"h2\">",
"     Genetic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testing for factor XII mutations is of limited usefulness because the majority of them do not have identifiable FXII mutations. The prevalence of this mutation in patients in the United States appears to be extremely low [",
"    <a class=\"abstract\" href=\"UTD.htm?4/61/5080/abstract/24\">",
"     24",
"    </a>",
"    ]. However, the test is available through some commercial laboratories [",
"    <a class=\"abstract\" href=\"UTD.htm?4/61/5080/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6433225\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnoses of hereditary forms of angioedema are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33864?source=see_link&amp;anchor=H12#H12\">",
"     \"Hereditary angioedema: Pathogenesis and diagnosis\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10254259\">",
"    <span class=\"h3\">",
"     Idiopathic angioedema",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary disorder in the differential diagnosis of type III HAE is idiopathic angioedema. This disorder must be excluded before the diagnosis of type III HAE can be assigned, especially without a family history or if testing for factor XII mutations is not performed or shows no mutations. (See",
"    <a class=\"local\" href=\"#H10254556\">",
"     'Exclude idiopathic angioedema'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6433232\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment options for HAE with normal C1 INH are overall similar to those for HAE types I and II and may also be divided into management of acute attacks and prophylactic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/61/5080/abstract/31\">",
"     31",
"    </a>",
"    ]. However, treatment experience is limited, and most evidence at this time is anecdotal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33657?source=see_link\">",
"     \"Hereditary angioedema: Treatment of acute attacks\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/61/29658?source=see_link\">",
"     \"Hereditary angioedema: Prevention of attacks\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6433246\">",
"    <span class=\"h2\">",
"     Treatment of acute attacks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with acute symptoms involving the upper airway are at risk for fatal asphyxiation. Assessment and protection of the upper airway is the first and most important management issue in the patient with an acute attack involving any part of the airway, because none of the available therapies can be considered universally effective. In addition, these agents take time to work, and the patient's airway must be protected in the interim.",
"   </p>",
"   <p>",
"    Intubation should be performed immediately if stridor or signs of respiratory arrest are present. A clinician trained in difficult airway management should be summoned if possible, because failed attempts can lead to fatal obstruction. Emergent cricothyroidotomy may be required in rare cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4905?source=see_link\">",
"     \"Emergent surgical cricothyrotomy (cricothyroidotomy)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once the patient is assessed and either intubated or deemed stable, additional therapies can be considered. Transfer to the intensive care unit should be arranged. Frequent and meticulous monitoring of airway status should continue throughout the course of the attack until complete resolution, and patients should not be discharged until all airway symptoms have resolved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1660976\">",
"    <span class=\"h3\">",
"     Therapies to reverse angioedema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data on the effectiveness of different therapies for type III HAE are limited to small, uncontrolled trials and case reports.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/36/4675?source=see_link\">",
"       Icatibant",
"      </a>",
"      is a bradykinin type 2 receptor antagonist that has been effective in treating acute symptoms in small numbers of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?4/61/5080/abstract/32,33\">",
"       32,33",
"      </a>",
"      ]. In an open-label, noncomparative prospective study including eight patients with HAE type III, most symptoms improved rapidly following icatibant self-administration, although some attacks required a second or third injection of the drug [",
"      <a class=\"abstract\" href=\"UTD.htm?4/61/5080/abstract/33\">",
"       33",
"      </a>",
"      ]. Dosing and administration are reviewed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33657?source=see_link&amp;anchor=H2297223#H2297223\">",
"       \"Hereditary angioedema: Treatment of acute attacks\", section on 'Icatibant dose and administration'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/23/23923?source=see_link\">",
"       Ecallantide",
"      </a>",
"      is a plasma kallikrein inhibitor, which was used successfully to treat HAE type III in one report [",
"      <a class=\"abstract\" href=\"UTD.htm?4/61/5080/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      C1 INH concentrate has also been used, although it is not obvious that it would be effective, since C1 inhibitor levels and function are normal in type III HAE. In one study, seven patients were treated with C1-INH concentrate for 63 attacks and it was subjectively effective for six of these individuals and ineffective for one [",
"      <a class=\"abstract\" href=\"UTD.htm?4/61/5080/abstract/9\">",
"       9",
"      </a>",
"      ]. Other cases reported lack of effect [",
"      <a class=\"abstract\" href=\"UTD.htm?4/61/5080/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Fresh frozen plasma (or solvent-detergent treated plasma) has not been reported for treatment of this disorder, to our knowledge.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with HAE type III tend not to respond to epinephrine, antihistamines, or glucocorticoids, similar to those with types I and II [",
"    <a class=\"abstract\" href=\"UTD.htm?4/61/5080/abstract/9,31\">",
"     9,31",
"    </a>",
"    ]. However, if the diagnosis is uncertain, these therapies should certainly not be withheld. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33657?source=see_link&amp;anchor=H23#H23\">",
"     \"Hereditary angioedema: Treatment of acute attacks\", section on 'Ineffective therapies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H527525427\">",
"    <span class=\"h2\">",
"     Avoidance of triggers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Triggers for episodes of angioedema include local trauma or physical pressure to the affected area, emotional stress, and certain medications [",
"    <a class=\"abstract\" href=\"UTD.htm?4/61/5080/abstract/9\">",
"     9",
"    </a>",
"    ]. Exogenous estrogens are the most consistently reported medication to worsen symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?4/61/5080/abstract/4\">",
"     4",
"    </a>",
"    ]. ACE inhibitors and angiotensin II receptor blockers (ARBs) have been implicated in case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?4/61/5080/abstract/8,35\">",
"     8,35",
"    </a>",
"    ]. In some patients, withdrawal of aggravating medications is sufficient to prevent most attacks and no other prophylactic therapy is needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H285896835\">",
"    <span class=\"h2\">",
"     Prophylactic treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term prophylaxis is given to decrease the overall number of attacks. It should be considered if attacks persist despite avoidance of aggravating medications for:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with more than one severe event per month",
"     </li>",
"     <li>",
"      Patients who are disabled (ie, unable to perform their usual activities) more than five days per month",
"     </li>",
"     <li>",
"      Patients who have experienced a laryngeal attack",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The decision to initiate prophylaxis must consider several other factors, including the availability of effective therapies for acute attacks (ie,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/36/4675?source=see_link\">",
"     icatibant",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/23/23923?source=see_link\">",
"     ecallantide",
"    </a>",
"    ), the patient&rsquo;s proximity to emergency care, the likelihood of side effects from long-term prophylactic therapies, and the patient's preferences. Each case must be considered individually.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H724447\">",
"    <span class=\"h3\">",
"     Choice of prophylactic agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both androgens and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"     tranexamic acid",
"    </a>",
"    have been administered to patients with type III HAE for prevention of angioedema attacks, and responses have been variable. It is the authors&rsquo; clinical experience that androgens are more consistently effective in both female and male patients.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"       Danazol",
"      </a>",
"      has been used with variable success in type III [",
"      <a class=\"abstract\" href=\"UTD.htm?4/61/5080/abstract/3,5,36\">",
"       3,5,36",
"      </a>",
"      ]. Androgens increase the levels of CI INH in humans and factor XII in rats as well as increase ACE levels in other animal studies [",
"      <a class=\"abstract\" href=\"UTD.htm?4/61/5080/abstract/28\">",
"       28",
"      </a>",
"      ]. Dosing and adverse effects are reviewed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/61/29658?source=see_link&amp;anchor=H15#H15\">",
"       \"Hereditary angioedema: Prevention of attacks\", section on 'Attenuated androgens'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/61/29658?source=see_link&amp;anchor=H40#H40\">",
"       \"Hereditary angioedema: Prevention of attacks\", section on 'Androgens'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"       Tranexamic acid",
"      </a>",
"      has also been used with some success [",
"      <a class=\"abstract\" href=\"UTD.htm?4/61/5080/abstract/3,9,37\">",
"       3,9,37",
"      </a>",
"      ]. Dosing and adverse effects are reviewed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/61/29658?source=see_link&amp;anchor=H24#H24\">",
"       \"Hereditary angioedema: Prevention of attacks\", section on 'Antifibrinolytics'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/61/29658?source=see_link&amp;anchor=H41#H41\">",
"       \"Hereditary angioedema: Prevention of attacks\", section on 'Tranexamic acid'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10254451\">",
"    <span class=\"h3\">",
"     Therapies of uncertain benefit",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infusions of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/57/23444?source=see_link\">",
"     C1 inhibitor concentrate",
"    </a>",
"    and progesterone preparations are of uncertain utility in preventing symptoms.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Regular infusions of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/57/23444?source=see_link\">",
"       C1 inhibitor concentrate",
"      </a>",
"      have been used successfully during the peripartum period in two women experiencing attacks during pregnancy [",
"      <a class=\"abstract\" href=\"UTD.htm?4/61/5080/abstract/16,20\">",
"       16,20",
"      </a>",
"      ]. However, it is unclear if there are potential adverse effects of providing more C1 inhibitor to a patient with normal levels of functional C1 INH. Since C1 INH is important in fibrinolytic, clotting, and kinin pathways, the authors recommend caution as there may be toxicity related to supraphysiologic amounts of C1 INH.",
"     </li>",
"     <li>",
"      Progesterone-only contraceptives have been reported to be helpful for some women with type III HAE [",
"      <a class=\"abstract\" href=\"UTD.htm?4/61/5080/abstract/9\">",
"       9",
"      </a>",
"      ]. However, it has not been demonstrated conclusively that the improvement in symptoms was attributable to use of progesterone or avoidance of estrogens.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6433253\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type III hereditary angioedema (HAE) is characterized by recurrent, self-limited episodes of skin swelling, tongue swelling, and episodes of abdominal pain. It is distinguished from other forms of hereditary angioedema (ie, types I and II) by the presence of normal complement studies. The disorder was described in 2000 and was reported initially in women, although male patients have since been identified. (See",
"      <a class=\"local\" href=\"#H6433169\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10208171\">",
"       'Background and terminology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HAE type III is clinically similar to HAE types I and II, although with certain distinctions, including more frequent facial and tongue swellings, less prominent abdominal symptoms, onset later in life (typically in adulthood), and different cutaneous findings. (See",
"      <a class=\"local\" href=\"#H6433307\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with type III HAE have normal C1 inhibitor function and plasma concentration, in contrast to those with types I and II. Some families have mutations in the coagulation factor XII gene, though the functional consequence of these mutations has not been determined. Some female patients have more severe disease when pregnant or taking exogenous estrogens, while others are not influenced by hormonal factors. (See",
"      <a class=\"local\" href=\"#H6433183\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of type III HAE is based on characteristic clinical features, a family history of angioedema, and normal complement studies (",
"      <a class=\"graphic graphic_table graphicRef83098 \" href=\"UTD.htm?21/58/22444\">",
"       table 1",
"      </a>",
"      ). In patients who lack a family history of angioedema, it is important to exclude idiopathic angioedema, a disorder in which complements studies are also normal. Idiopathic angioedema usually responds to therapy with antihistamines (often at supratherapeutic doses), alone or in combination with glucocorticoids. The presence of factor XII mutations, which are demonstrable in some patients with type III HAE, is another means of distinguishing the two disorders. (See",
"      <a class=\"local\" href=\"#H6433218\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with acute symptoms involving the tongue or upper airway, assessment and protection of the airway is the first and most important management issue, because none of the available therapies can be considered universally effective. (See",
"      <a class=\"local\" href=\"#H6433246\">",
"       'Treatment of acute attacks'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The options for acute and prophylactic therapy for HAE type III are very similar to those for HAE types I and II. However, information about the efficacy of various treatments for acute symptoms is limited. (See",
"      <a class=\"local\" href=\"#H6433232\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5080/abstract/1\">",
"      Bork K, G&uuml;l D, Dewald G. Hereditary angio-oedema with normal C1 inhibitor in a family with affected women and men. Br J Dermatol 2006; 154:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5080/abstract/2\">",
"      Bork K, G&uuml;l D, Hardt J, Dewald G. Hereditary angioedema with normal C1 inhibitor: clinical symptoms and course. Am J Med 2007; 120:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5080/abstract/3\">",
"      Bork K, Barnstedt SE, Koch P, Traupe H. Hereditary angioedema with normal C1-inhibitor activity in women. Lancet 2000; 356:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5080/abstract/4\">",
"      Binkley KE, Davis A 3rd. Clinical, biochemical, and genetic characterization of a novel estrogen-dependent inherited form of angioedema. J Allergy Clin Immunol 2000; 106:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5080/abstract/5\">",
"      Martin L, Degenne D, Toutain A, et al. Hereditary angioedema type III: an additional French pedigree with autosomal dominant transmission. J Allergy Clin Immunol 2001; 107:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5080/abstract/6\">",
"      Bork K, Fischer B, Dewald G. Recurrent episodes of skin angioedema and severe attacks of abdominal pain induced by oral contraceptives or hormone replacement therapy. Am J Med 2003; 114:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5080/abstract/7\">",
"      Binkley KE, Davis AE 3rd. Estrogen-dependent inherited angioedema. Transfus Apher Sci 2003; 29:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5080/abstract/8\">",
"      Frank MM, Gelfand JA, Atkinson JP. Hereditary angioedema: the clinical syndrome and its management. Ann Intern Med 1976; 84:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5080/abstract/9\">",
"      Bork K, Wulff K, Hardt J, et al. Hereditary angioedema caused by missense mutations in the factor XII gene: clinical features, trigger factors, and therapy. J Allergy Clin Immunol 2009; 124:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5080/abstract/10\">",
"      Bork K. Hereditary angioedema with normal c1 inhibition. Curr Allergy Asthma Rep 2009; 9:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5080/abstract/11\">",
"      Bork K, Meng G, Staubach P, Hardt J. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med 2006; 119:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5080/abstract/12\">",
"      Kaplan AP. Enzymatic pathways in the pathogenesis of hereditary angioedema: the role of C1 inhibitor therapy. J Allergy Clin Immunol 2010; 126:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5080/abstract/13\">",
"      Dewald G, Bork K. Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. Biochem Biophys Res Commun 2006; 343:1286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5080/abstract/14\">",
"      Bork K, Wulff K, Meinke P, et al. A novel mutation in the coagulation factor 12 gene in subjects with hereditary angioedema and normal C1-inhibitor. Clin Immunol 2011; 141:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5080/abstract/15\">",
"      Cichon S, Martin L, Hennies HC, et al. Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. Am J Hum Genet 2006; 79:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5080/abstract/16\">",
"      Bouillet L, Ponard D, Rousset H, et al. A case of hereditary angio-oedema type III presenting with C1-inhibitor cleavage and a missense mutation in the F12 gene. Br J Dermatol 2007; 156:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5080/abstract/17\">",
"      Bell CG, Kwan E, Nolan RC, Baumgart KW. First molecular confirmation of an Australian case of type III hereditary angioedema. Pathology 2008; 40:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5080/abstract/18\">",
"      Nagy N, Greaves MW, Tanaka A, et al. Recurrent European missense mutation in the F12 gene in a British family with type III hereditary angioedema. J Dermatol Sci 2009; 56:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5080/abstract/19\">",
"      Prieto A, Tornero P, Rubio M, et al. Missense mutation Thr309Lys in the coagulation factor XII gene in a Spanish family with hereditary angioedema type III. Allergy 2009; 64:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5080/abstract/20\">",
"      Picone O, Donnadieu AC, Brivet FG, et al. Obstetrical Complications and Outcome in Two Families with Hereditary Angioedema due to Mutation in the F12 Gene. Obstet Gynecol Int 2010; 2010:957507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5080/abstract/21\">",
"      Baeza ML, Rodr&iacute;guez-Marco A, Prieto A, et al. Factor XII gene missense mutation Thr328Lys in an Arab family with hereditary angioedema type III. Allergy 2011; 66:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5080/abstract/22\">",
"      Bork K. Hereditary angioedema with normal C1 inhibitor activity including hereditary angioedema with coagulation factor XII gene mutations. Immunol Allergy Clin North Am 2006; 26:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5080/abstract/23\">",
"      Bork K, Kleist R, Hardt J, Witzke G. Kallikrein-kinin system and fibrinolysis in hereditary angioedema due to factor XII gene mutation Thr309Lys. Blood Coagul Fibrinolysis 2009; 20:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5080/abstract/24\">",
"      Frazer-Abel A, Giclas PC. Update on laboratory tests for the diagnosis and differentiation of hereditary angioedema and acquired angioedema. Allergy Asthma Proc 2011; 32 Suppl 1:S17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5080/abstract/25\">",
"      Duan QL, Binkley K, Rouleau GA. Genetic analysis of Factor XII and bradykinin catabolic enzymes in a family with estrogen-dependent inherited angioedema. J Allergy Clin Immunol 2009; 123:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5080/abstract/26\">",
"      Serrano C, Guilarte M, Tella R, et al. Oestrogen-dependent hereditary angio-oedema with normal C1 inhibitor: description of six new cases and review of pathogenic mechanisms and treatment. Allergy 2008; 63:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5080/abstract/27\">",
"      Hentges F, Hilger C, Kohnen M, Gilson G. Angioedema and estrogen-dependent angioedema with activation of the contact system. J Allergy Clin Immunol 2009; 123:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5080/abstract/28\">",
"      Binkley KE. Factor XII mutations, estrogen-dependent inherited angioedema, and related conditions. Allergy Asthma Clin Immunol 2010; 6:16.",
"     </a>",
"    </li>",
"    <li>",
"     Factor 12 mutational analysis is available from GeneDx. www.genedx.com (Accessed on May 10, 2012).",
"    </li>",
"    <li>",
"     Factor 12 SNP analysis is available through National Jewish Health Advanced Diagnostics Laboratories. www.nationaljewish.org/research/diagnostics/adx (Accessed on May 10, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5080/abstract/31\">",
"      Bork K. Diagnosis and treatment of hereditary angioedema with normal C1 inhibitor. Allergy Asthma Clin Immunol 2010; 6:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5080/abstract/32\">",
"      Bouillet L, Boccon-Gibod I, Ponard D, et al. Bradykinin receptor 2 antagonist (icatibant) for hereditary angioedema type III attacks. Ann Allergy Asthma Immunol 2009; 103:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5080/abstract/33\">",
"      Boccon-Gibod I, Bouillet L. Safety and efficacy of icatibant self-administration for acute hereditary angioedema. Clin Exp Immunol 2012; 168:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5080/abstract/34\">",
"      Cronin JA, Maples KM. Treatment of an acute attack of type III hereditary angioedema with ecallantide. Ann Allergy Asthma Immunol 2012; 108:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5080/abstract/35\">",
"      Bork K, Dewald G. Hereditary angioedema type III, angioedema associated with angiotensin II receptor antagonists, and female sex. Am J Med 2004; 116:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5080/abstract/36\">",
"      Herrmann G, Schneider L, Krieg T, et al. Efficacy of danazol treatment in a patient with the new variant of hereditary angio-oedema (HAE III). Br J Dermatol 2004; 150:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5080/abstract/37\">",
"      Vitrat-Hincky V, Gompel A, Dumestre-Perard C, et al. Type III hereditary angio-oedema: clinical and biological features in a French cohort. Allergy 2010; 65:1331.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16529 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-76F9A528C7-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_61_5080=[""].join("\n");
var outline_f4_61_5080=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6433253\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6433169\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6433176\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10208171\">",
"      BACKGROUND AND TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6433307\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6791385\">",
"      Unique characteristics of type III",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6433183\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6433190\">",
"      Mutations in the FXII gene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6433197\">",
"      Other genetic mutations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6433204\">",
"      Role of estrogens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6433218\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10254556\">",
"      Exclude idiopathic angioedema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1657995\">",
"      Genetic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6433225\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10254259\">",
"      - Idiopathic angioedema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6433232\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6433246\">",
"      Treatment of acute attacks",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1660976\">",
"      - Therapies to reverse angioedema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H527525427\">",
"      Avoidance of triggers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H285896835\">",
"      Prophylactic treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H724447\">",
"      - Choice of prophylactic agent",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10254451\">",
"      - Therapies of uncertain benefit",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6433253\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/16529\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/16529|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?1/50/1825\" title=\"algorithm 1\">",
"      C1-INH deficiency diagnostic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/16529|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/51/41791\" title=\"figure 1\">",
"      HAE pathways",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/16529|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/15/26879\" title=\"picture 1\">",
"      HAE prodromal rash",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/16529|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/58/22444\" title=\"table 1\">",
"      Comparison of complement studies in angioedema disorders",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/17/15641?source=related_link\">",
"      An overview of angioedema: Clinical features, diagnosis, and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4905?source=related_link\">",
"      Emergent surgical cricothyrotomy (cricothyroidotomy)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19272?source=related_link\">",
"      Hereditary angioedema: Epidemiology, clinical manifestations, exacerbating factors, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33864?source=related_link\">",
"      Hereditary angioedema: Pathogenesis and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/61/29658?source=related_link\">",
"      Hereditary angioedema: Prevention of attacks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33657?source=related_link\">",
"      Hereditary angioedema: Treatment of acute attacks",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_61_5081="Folic acid for prevention of neural tube defects";
var content_f4_61_5081=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Folic acid for prevention of neural tube defects",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/61/5081/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/61/5081/contributors\">",
"     Lauri Hochberg, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/61/5081/contributors\">",
"     Joanne Stone, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/61/5081/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/61/5081/contributors\">",
"     Louise Wilkins-Haug, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/61/5081/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/61/5081/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/61/5081/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neural tube defects (NTD) are the second most prevalent congenital anomaly in the United States, second only to cardiac malformations, and they are associated with substantial morbidity and mortality.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     Folic acid",
"    </a>",
"    supplementation and dietary fortification decrease the occurrence and recurrence of these anomalies and are recommended for women planning pregnancy or capable of becoming pregnant.",
"   </p>",
"   <p>",
"    The role of folate in the prevention of NTDs will be discussed here. Prenatal screening and diagnosis of NTDs are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/35/25145?source=see_link\">",
"     \"Prenatal screening and diagnosis of neural tube defects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     FOLATE AND FOLIC ACID",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the terms are used interchangeably, folate is a water-soluble B vitamin (B9) that occurs naturally in foods such as beef liver, leafy green vegetables, oranges, and legumes, whereas",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    is the synthetic form of folate that is found in supplements and added to fortified foods (",
"    <a class=\"graphic graphic_table graphicRef72855 \" href=\"UTD.htm?6/58/7085\">",
"     table 1",
"    </a>",
"    ). The bioavailability of folic acid from supplements and folic acid fortified foods appears to be substantially higher than folate bioavailability from consumption of natural foods [",
"    <a class=\"abstract\" href=\"UTD.htm?4/61/5081/abstract/1\">",
"     1",
"    </a>",
"    ]. Bioavailability is affected by several factors, including whether the food is raw or cooked, how it is cooked, the combination of foods consumed, and host factors.",
"   </p>",
"   <p>",
"    Varying degrees of folate deficiency may result from low carbohydrate diets, since bread and pasta are made of fortified grain; some medications (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    ); high consumption of foods designated as \"organic,\" which are exempt from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    fortification regulations; and medical or surgical conditions associated with malabsorption (eg, celiac disease, Crohn's disease, intestinal resection or bypass).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adequate folate is critical for cell division due to its essential role in the synthesis of nucleic and certain amino acids. Folate deficiency may impede adequate cell turnover during a critical point in the closure of the neural tube, thereby resulting in incomplete formation. Several lines of evidence support the hypothesis of a link between",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    deficiency and NTDs:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Randomized trials have consistently shown that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      supplementation markedly reduces the incidence of NTDs [",
"      <a class=\"abstract\" href=\"UTD.htm?4/61/5081/abstract/2-9\">",
"       2-9",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      antagonists (dihydrofolate reductase inhibitors and others) increases the risk of NTDs [",
"      <a class=\"abstract\" href=\"UTD.htm?4/61/5081/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The concentrations of serum and red blood cell folate are lower in women carrying a child with a NTD than in pregnancies with unaffected fetuses. A systematic review determined that, in the first trimester, serum folate levels were 0.6",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      lower and red cell folate levels were 77",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      lower in pregnancies complicated by NTDs than in unaffected controls [",
"      <a class=\"abstract\" href=\"UTD.htm?4/61/5081/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The biochemical profile of women who have had pregnancies affected by NTDs shows not only a low (but not deficient) concentration of serum folate, but also an elevated concentration of homocysteine and methylmalonic acid, and a reduced concentration of vitamin B12&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?4/61/5081/abstract/12\">",
"       12",
"      </a>",
"      ]. This suggests that an abnormality of folate metabolism, rather than a simple nutritional deficiency, is present [",
"      <a class=\"abstract\" href=\"UTD.htm?4/61/5081/abstract/13\">",
"       13",
"      </a>",
"      ]. In addition, amniotic fluid levels of homocysteine are abnormally high when the fetus has a NTD, suggesting that a subset of NTDs could be due to a primary or secondary maternal or fetal derangement of homocysteine metabolism. [",
"      <a class=\"abstract\" href=\"UTD.htm?4/61/5081/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Some individuals develop antibodies to folate receptors, but whether auto-antibody blockade of folate receptors leads to development of NTDs is unclear. In one study, these antibodies were detected in 9 of 12 women with a history of a pregnancy complicated by a NTD, but in only 2 of 20 women with no such history [",
"      <a class=\"abstract\" href=\"UTD.htm?4/61/5081/abstract/15\">",
"       15",
"      </a>",
"      ]. In another study, there was no significant difference in the frequency of folate-receptor blocking or binding antibodies among mothers from families affected by NTDs, fathers from families affected by NTDs, and men and women with no family history of birth defects [",
"      <a class=\"abstract\" href=\"UTD.htm?4/61/5081/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Genetic etiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;MTHFR and MTHFD1 are key players in folate metabolism. Polymorphisms of genes for folate-dependent enzymes have been associated with development of NTDs, as well as some other complex diseases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     MTHFR polymorphisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the enzymes that regulates folate and homocysteine levels, methylenetetrahydrofolate reductase (MTHFR), has a common genetic variant (677C to T) that has reduced catalytic activity. Individuals homozygous (TT) for this thermolabile variant have increased plasma homocysteine levels, which can be lowered by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    supplementation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/37/19034?source=see_link\">",
"     \"Overview of homocysteine\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Both TT and heterozygous (CT) genotypes are associated with a low tissue concentration of folate and an increased risk of NTDs, but the deficiency is greater and the risk of anomaly is higher in TT individuals. The progressively increasing risk of NTDs in affected individuals was illustrated in a population-based study from Ireland that showed, compared to normal controls (CC), the relative risk of NTDs was 1.52 with the CT genotype and 2.56 with the TT genotype [",
"    <a class=\"abstract\" href=\"UTD.htm?4/61/5081/abstract/17\">",
"     17",
"    </a>",
"    ]. These genotype variants accounted for one-quarter of NTDs in Ireland.",
"   </p>",
"   <p>",
"    Additional studies have confirmed the higher frequency of the TT genotype in individuals with NTDs and their first degree relatives than in the general population (16 versus 9 percent), suggesting that the mutation is a specific genetic risk factor for NTDs [",
"    <a class=\"abstract\" href=\"UTD.htm?4/61/5081/abstract/13,18-21\">",
"     13,18-21",
"    </a>",
"    ]. However, other reports have not found an association between the TT genotype and NTDs [",
"    <a class=\"abstract\" href=\"UTD.htm?4/61/5081/abstract/22-25\">",
"     22-25",
"    </a>",
"    ]. This discordancy has not been fully explained, but is likely related to differences in folate intake and other unrecognized confounders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     MTHFD1 polymorphisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gene MTHFD1 encodes a protein with three enzymatic activities that play important roles in folate metabolism. Variants in MTHFD1 have been associated with NTDS; however, these associations are controversial and require further investigation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/61/5081/abstract/26-30\">",
"     26-30",
"    </a>",
"    ]. The mechanism whereby genetic variants in MTHFD1 may affect neural tube closure is not known, but does not appear to be related to maternal serum folate concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?4/61/5081/abstract/26\">",
"     26",
"    </a>",
"    ]. It is hypothesized that these mothers may have less efficient purine or pyrimidine synthesis, which is critical during early embryo development.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     FOLIC ACID SUPPLEMENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Folate supplementation can reduce the risk of NTDs, presumably by preventing nutritional deficiency and by overcoming disruptions in folate metabolism related to underlying genetic variation in folate-related genes.",
"   </p>",
"   <p>",
"    Because neural tube",
"    <span class=\"nowrap\">",
"     development/closure",
"    </span>",
"    occurs within the first four weeks of embryonic life (ie, by six weeks of gestation) and before many women know they are pregnant or meet with a clinician,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    supplementation should be started at least one month prior to conception and continue throughout the first trimester. The dose (0.4 to 5 mg) depends on the woman's risk status. Furthermore, because many pregnancies are unplanned, folic acid supplementation is recommended for all women of childbearing potential.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     High risk women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with a previous child with a NTD and those taking anticonvulsants associated with development of NTDs (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ) are at highest risk of having an affected child in a future pregnancy (",
"    <a class=\"graphic graphic_table graphicRef63266 \" href=\"UTD.htm?22/33/23068\">",
"     table 2",
"    </a>",
"    ). Periconceptional",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    supplementation (4 to 5 mg) is recommended for these women to reduce the occurrence and recurrence of affected infants [",
"    <a class=\"abstract\" href=\"UTD.htm?4/61/5081/abstract/31-34\">",
"     31-34",
"    </a>",
"    ]. Periconceptional supplementation reduces the risk of recurrent NTDs by about 70 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/61/5081/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women should be advised",
"    <strong>",
"     not",
"    </strong>",
"    to attempt to achieve the 4 mg daily dosage of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    by taking multiple multivitamins containing folic acid because of the possibility of ingesting harmful levels of other vitamins, such as Vitamin A. One prenatal vitamin once per day and a 1 mg of folic acid three times per day is a practical means of ingesting a total dose of 4 mg per day.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Previously affected pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend folate supplementation with 4",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for those patients at elevated risk. The recommendation for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    supplementation is based upon results of the United Kingdom's Medical Research Council Vitamin Study Research Group randomized, double-blind prevention trial [",
"    <a class=\"abstract\" href=\"UTD.htm?4/61/5081/abstract/35\">",
"     35",
"    </a>",
"    ]. The purpose of this trial was to determine whether supplementation with folic acid (4 mg) around the time of conception could prevent NTDs in patients at risk because of a previously affected pregnancy. Pregnancies supplemented with folic acid had a 72 percent reduction in the incidence of NTDs.",
"   </p>",
"   <p>",
"    Although the 4 mg dose was effective, it is unclear what the minimal effective dose is and whether larger doses would be more effective. Wald has recommended a 5 mg",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    supplement [",
"    <a class=\"abstract\" href=\"UTD.htm?4/61/5081/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. The rationale for this approach is that serum folate concentrations increase by 0.94",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (95% CI 0.77-1.10) for every 0.1",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    increase in folic acid intake in women aged 20 to 35 years, and doubling of serum folate concentration roughly halves the risk of a NTD. Therefore, a supplement of 0.4",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    should reduce the risk of NTDs by about 36 percent, a supplement of 1",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    should reduce the risk of NTDs by about 57 percent, and a supplement of 5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    should reduce the risk of NTDs by about by about 85 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Anticonvulsant therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;No trials to determine the effective dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    supplementation in women taking anticonvulsants have been performed. The 4 mg dose has been suggested based upon extrapolation from studies in women with a previously affected child [",
"    <a class=\"abstract\" href=\"UTD.htm?4/61/5081/abstract/35\">",
"     35",
"    </a>",
"    ]. In general, preconception doses of folate are continued throughout pregnancy. Some experts suggest that when a woman with epilepsy who is taking anticonvulsants becomes pregnant, plasma folate levels should be monitored and the dose of folic acid adjusted to achieve a concentration above 4",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (9",
"    <span class=\"nowrap\">",
"     nmol/L).",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22633?source=see_link\">",
"     \"Risks associated with epilepsy and pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/16/15625?source=see_link\">",
"     \"Management of epilepsy and pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H106393937\">",
"    <span class=\"h3\">",
"     Other conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some experts recommend high dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    supplements for women at intermediate risk of having a child with a NTD (eg, insulin dependent diabetes, obesity with BMI &gt;35",
"    <span class=\"nowrap\">",
"     kg/m2,",
"    </span>",
"    family history of neural tube defect, and women with certain folate-enzyme genotypes, malabsorption disorders, or taking anti-folate medications [",
"    <a class=\"abstract\" href=\"UTD.htm?4/61/5081/abstract/38\">",
"     38",
"    </a>",
"    ]).",
"   </p>",
"   <p>",
"    Although some of these experts consider pregestational diabetes an additional risk factor for NTDs, others believe glucose-mediated neural tube defects probably are not prevented by folate supplementation and therefore additional supplementation is ineffective in women with diabetes. However, data from an animal study supports the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    supplementation in women with diabetes. In this study, folic acid supplementation of diabetic mice not only reduced the incidence of NTDs (NTD incidence 6 percent versus 28.4 percent in controls), but also cardiovascular and skeletal malformations [",
"    <a class=\"abstract\" href=\"UTD.htm?4/61/5081/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Society of Obstetricians and Gynaecologists of Canada suggests that women with health risks, including insulin dependent diabetes, BMI &gt;35",
"    <span class=\"nowrap\">",
"     kg/m2,",
"    </span>",
"    family history of NTD, and belonging to a high-risk ethnic group (eg Sikh), increase their dietary intake of folate-rich foods and take daily folate supplementation of 5 mg",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    , beginning at least three months before conception and continuing until 10 to 12 weeks post conception [",
"    <a class=\"abstract\" href=\"UTD.htm?4/61/5081/abstract/40\">",
"     40",
"    </a>",
"    ]. They also suggest this approach for women who have a history of poor compliance with medications and additional lifestyle issues of variable diet, no consistent birth control, and possible teratogenic substance use (alcohol, tobacco, recreational non-prescription drugs), as the higher folic acid dose may obtain a more adequate serum red blood cell folate level in the setting of irregular vitamin",
"    <span class=\"nowrap\">",
"     /",
"    </span>",
"    folic acid intake.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Primary prevention in low risk women",
"    </span>",
"    &nbsp;&mdash;&nbsp;The third National Health and Nutrition Examination Survey (from 1989 to 1991, prior to folate supplementation and food fortification) reported that the mean folate intake of reproductive aged women in the United States was 230 mcg per day [",
"    <a class=\"abstract\" href=\"UTD.htm?4/61/5081/abstract/41\">",
"     41",
"    </a>",
"    ]. This is below the level that is required to maintain normal blood folate levels during pregnancy, a period of increased folate demand. To prevent folate deficiency and its consequences in periconceptional and pregnant women,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    supplementation and food fortification programs were introduced and designed to ensure a minimum daily intake of 400 mcg folate [",
"    <a class=\"abstract\" href=\"UTD.htm?4/61/5081/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple national organizations have conducted educational campaigns to inform women of childbearing age about the need for additional folate intake. Nevertheless, a 2007 Gallup survey found that only 40 percent of women of childbearing age in the United States reported daily consumption of a vitamin containing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    , 61 to 89 percent knew that folic acid prevents birth defects, and 6 to 16 percent were aware that it should be taken before conception [",
"    <a class=\"abstract\" href=\"UTD.htm?4/61/5081/abstract/43\">",
"     43",
"    </a>",
"    ]. Young women (under age 24 years) were the least well-informed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Folic acid supplements",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most women (95 percent) who deliver infants with NTDs have no history of a prior affected pregnancy and are not on anticonvulsants [",
"    <a class=\"abstract\" href=\"UTD.htm?4/61/5081/abstract/44\">",
"     44",
"    </a>",
"    ]; therefore, measures to prevent recurrent NTDs will have a small impact on the incidence of this disorder. For this reason, periconceptional",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    supplementation is recommended for all women of reproductive potential to decrease the occurrence of a first affected pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/61/5081/abstract/31,32,34,45\">",
"     31,32,34,45",
"    </a>",
"    ]. This recommendation is supported by a meta-analyses of 41 studies that found use of multivitamin supplements provided consistent protection against NTDs (OR 0.67, 95% CI 0.58-0.77 in case control studies; OR 0.52, 95% CI 0.39-0.69 in cohort and randomized trials) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/61/5081/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The minimum dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    that is effective is unknown; a wide range of doses has been used and found to be effective [",
"    <a class=\"abstract\" href=\"UTD.htm?4/61/5081/abstract/2-9\">",
"     2-9",
"    </a>",
"    ]. The United States Preventive Services Task Force (USPSTF) recommends that all women of reproductive age planning or capable of pregnancy take a supplement containing 0.4 mg to 0.8 mg of folic acid daily to reduce their risk of having a child with a NTD [",
"    <a class=\"abstract\" href=\"UTD.htm?4/61/5081/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Maximum benefit is derived from consumption from one month before through two to three months after conception; however, daily intake for all women of childbearing age is advised since over 50 percent of pregnancies in the United States are unplanned [",
"    <a class=\"abstract\" href=\"UTD.htm?4/61/5081/abstract/48\">",
"     48",
"    </a>",
"    ]. Statements by the American College of Obstetricians and Gynecologists, the American Academy of Family Physicians, and the American Academy of Pediatrics concur with this recommendation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/61/5081/abstract/31,34,49\">",
"     31,34,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Doses well above this amount are probably necessary to maximally reduce the risk of neural tube defects; a conservative dose was chosen to minimize the risk of masking B12 deficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/0/5130?source=see_link\">",
"     \"Diagnosis and treatment of vitamin B12 and folate deficiency\"",
"    </a>",
"    .) Another advantage of a dose less than 1 mg is that (in the United States) pills containing 1 or more milligrams of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    require a prescription (prescription prenatal vitamins typically contain 1 mg of folic acid). As discussed above, multiple multivitamin pills should not be consumed to achieve this dose because of the risk of vitamin A toxicity.",
"   </p>",
"   <p>",
"    Consumption of foods fortified with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    is also useful (see below). It is reasonable to recommend both a daily multivitamin and consumption of high folate and folic acid fortified foods since folate intake from the latter may be erratic and reduced by dieting, which is common in this age group [",
"    <a class=\"abstract\" href=\"UTD.htm?4/61/5081/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Folate levels can be measured in plasma, serum, and red blood cells. However, plasma and serum levels reflect only the transient concentration of the vitamin between absorption and storage. Red blood cell folate concentration is a more accurate assessment of folate status, although its measurement is not highly reproducible [",
"    <a class=\"abstract\" href=\"UTD.htm?4/61/5081/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. Due to this variability in measurements and unclear correlation with outcome, we are not recommending routinely measuring folate concentration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/0/5130?source=see_link\">",
"     \"Diagnosis and treatment of vitamin B12 and folate deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Food fortification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    supplements are highly effective in preventing NTDs, supplementation alone is not an effective strategy for prevention because of poor patient compliance [",
"    <a class=\"abstract\" href=\"UTD.htm?4/61/5081/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. Therefore, in 1998 the US Food and Drug Administration decided to fortify the food supply with folic acid; specifically, the agency mandated that enriched grain products be fortified with 140 micrograms of folic acid per 100 grams of product [",
"    <a class=\"abstract\" href=\"UTD.htm?4/61/5081/abstract/55\">",
"     55",
"    </a>",
"    ]. This is a low level of fortification; it was designed to keep 90 percent of the population consuming &lt;1000 mcg folic acid daily from all sources (food and supplements) and thus not mask vitamin B12 deficiency. The validity of this rationale has been challenged repeatedly [",
"    <a class=\"abstract\" href=\"UTD.htm?4/61/5081/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is generally believed that food fortification alone is unlikely to provide adequate intake of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    for all women [",
"    <a class=\"abstract\" href=\"UTD.htm?4/61/5081/abstract/57\">",
"     57",
"    </a>",
"    ]; therefore, folic acid supplements are still recommended for women of childbearing age. However, there is also some evidence that current levels of folic acid fortification are sufficient to prevent most folate-sensitive NTDs [",
"    <a class=\"abstract\" href=\"UTD.htm?4/61/5081/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The success of food fortification programs is illustrated by the following representative studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Centers for Disease Control analyzed data from a population-based surveillance system that included 90 percent of live births in the United States. From 1995-1996 (before mandatory food fortification) to 1998-1999 (after mandatory food fortification), the birth prevalence of all neural tube defects, spina bifida, and anencephaly declined by 19, 23, and 11 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?4/61/5081/abstract/59\">",
"       59",
"      </a>",
"      ]. The number of annual NTD-affected birth defects was most recently calculated from just after mandatory food fortification (1999 to 2000) to several years postfortification (2003 to 2005) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/61/5081/abstract/60\">",
"       60",
"      </a>",
"      ]. During this period, there was a 6.9 percent decline in spina bifida-affected pregnancies in the US (from 2.04 to 1.90 cases per 10,000 live births). Non-Hispanic black mothers accounted for almost all of this reduction (19.8 percent decrease); there was no significant decrease in spina bifida births to nonHispanic white and Hispanic women. This discordancy may be related to differences in eating habits, genetic factors, or the limitations of birth certificate data, which can be inaccurate and do not include stillbirths or pregnancy terminations. Factors other than fortification, such as prenatal serum and ultrasound screening programs for fetal anomalies and womens' attitudes about pregnancy termination, may have contributed to these findings.",
"     </li>",
"     <li>",
"      The benefit of national policy of food fortification was also suggested by data from Canada, where the incidence of NTDs (as ascertained in live births, stillbirths, and pregnancy terminations) decreased by about 50 percent after initiation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      fortification of grain products [",
"      <a class=\"abstract\" href=\"UTD.htm?4/61/5081/abstract/61\">",
"       61",
"      </a>",
"      ]. The greater reduction in NTDs in Canada compared with the United States may be related to more complete ascertainment of cases. A significant reduction in NTDs after food fortification has also been observed in South America [",
"      <a class=\"abstract\" href=\"UTD.htm?4/61/5081/abstract/62,63\">",
"       62,63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In addition, a study including over 60,000 women revealed a 32 percent decrease in the incidence of high MSAFP levels (values greater than 2.75 MoM) since mandatory food fortification was introduced in the United States [",
"      <a class=\"abstract\" href=\"UTD.htm?4/61/5081/abstract/64\">",
"       64",
"      </a>",
"      ]. Since MSAFP is performed in the midtrimester, this large decrease reflects the combined effects of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      supplementation and food fortification on the incidence of NTDs better than data derived from birth certificates. However, since most mothers with elevated MSAFP values do not have fetuses with NTDs and placental factors may cause an elevated MSAFP, folate may be exerting its effects on MSAFP through improved placentation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H183508197\">",
"    <span class=\"h3\">",
"     Fortified oral contraceptives",
"    </span>",
"    &nbsp;&mdash;&nbsp;A combination tablet containing an oral contraceptive (20 mcg ethinyl",
"    <span class=\"nowrap\">",
"     estradiol/3",
"    </span>",
"    mg drospirenone) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    (451 mcg levomefolate) is available. A decision analysis estimated that if all women in the US using oral contraceptives used folate-fortified contraceptive pills rather than traditional contraceptive pills, the number of NTDs in these women would fall by 24 to 31 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/61/5081/abstract/65\">",
"     65",
"    </a>",
"    ]. This benefit was based on the assumption that women who had achieved steady-state folate levels would sometimes miss pills, resulting in unplanned pregnancy, and that folate levels would be maintained for 20 weeks after discontinuation of contraception, the period when planned or unplanned pregnancies often occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Risks of folic acid supplementation during pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A potential harm of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    supplementation is the possibility of masking vitamin B12 deficiency, a condition that is rare in reproductive-aged women. Theoretical risks include drug interactions, allergic reactions, carcinogenic effects, and increased twinning. There is no evidence that folic acid supplementation for prevention of NTDs has resulted in masking of vitamin B12 deficiency, allergic reactions, or unexpected drug interactions; an effect on twinning is uncertain (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/46/40682?source=see_link&amp;anchor=H3#H3\">",
"     \"Twin pregnancy: Prenatal issues\", section on 'Incidence and epidemiology'",
"    </a>",
"    ). [",
"    <a class=\"abstract\" href=\"UTD.htm?4/61/5081/abstract/47\">",
"     47",
"    </a>",
"    ]. Routine vitamin B12 supplementation is not recommended for women taking folic acid supplements",
"   </p>",
"   <p>",
"    The long-term risk of folate supplementation during pregnancy was evaluated in a 35-year follow-up of women who participated in a placebo controlled randomized trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    supplementation in pregnancy performed from 1966 to 1967 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/61/5081/abstract/66\">",
"     66",
"    </a>",
"    ]. A nonsignificant increase in breast cancer mortality occurred in women who received 0.2 or 5 mg folic acid supplementation daily during pregnancy. This result may well have been due to chance [",
"    <a class=\"abstract\" href=\"UTD.htm?4/61/5081/abstract/67\">",
"     67",
"    </a>",
"    ]. The weight of epidemiologic evidence indicates that low folate levels are associated with an increased risk of breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?4/61/5081/abstract/68-70\">",
"     68-70",
"    </a>",
"    ], thus casting doubt on the findings reported in this study. At this time, no change in the recommendations for folic acid supplementation in pregnancy is appropriate, but further study is clearly warranted.",
"   </p>",
"   <p>",
"    The risks and benefits of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    supplementation in nonpregnant individuals is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36586?source=see_link&amp;anchor=H3#H3\">",
"     \"Vitamin supplementation in disease prevention\", section on 'Folic acid'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Treatment failures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adequate intake of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    will not prevent all cases of NTDs. There are situations in which the risk of NTDs may not be reduced by any level of folic acid supplementation (ie, nonfolate sensitive NTDs), such as poor first trimester glycemic control in women with diabetes, hyperthermia, NTDs associated with genetic syndromes, and women with immune factors (presence of antibodies to folate receptors) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/61/5081/abstract/31\">",
"     31",
"    </a>",
"    ]. Although the mechanisms for development of NTDs in these cases are not completely defined, they do not appear to rely primarily upon folate deficiency. The percentage of NTDs that is folic acid preventable is unclear; estimates range from 50 to 70 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/61/5081/abstract/71\">",
"     71",
"    </a>",
"    ]. Because nonfolate sensitive NTDs cannot always be identified with certainty, folate is recommended for all women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Possible additional benefits",
"    </span>",
"    &nbsp;&mdash;&nbsp;In individual trials,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    supplementation, usually as part of a multivitamin, has been associated with a variety of benefits unrelated to NTDs, but these relationships require further study and confirmation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/44/28362?source=see_link&amp;anchor=H21218290#H21218290\">",
"     \"Nutrition in pregnancy\", section on 'Other potential benefits'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/15/6387?source=see_link\">",
"       \"Patient information: Vitamin B12 deficiency and folate (folic acid) deficiency (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Folate deficiency can cause neural tube defects and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      supplementation can prevent them. Periconceptional folic acid supplementation reduces the incidence of neural tube defects by 50 to 70 percent. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Folic acid supplementation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend periconceptional",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      supplementation to reduce the occurrence and recurrence of neural tube defects (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). The optimal dose is unclear. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Folic acid supplementation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For women with a previously affected child, we suggest a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      supplement of 4 mg per day beginning at least one month prior to conception and continuing through the first trimester (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'High risk women'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      , and for women with pregestational diabetes, we suggest 4 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      supplementation per day beginning at least one month prior to conception and continuing through the first trimester (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'High risk women'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/16/15625?source=see_link\">",
"       \"Management of epilepsy and pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For all other women of reproductive potential, we suggest taking one multivitamin containing 0.4 to 0.8 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      daily (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Folic acid supplements'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In women with epilepsy, preconception doses of folate are generally continued throughout pregnancy. Some experts suggest monitoring plasma folate levels and adjusting the dose to achieve a concentration above 4",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      (9",
"      <span class=\"nowrap\">",
"       nmol/L).",
"      </span>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/16/15625?source=see_link\">",
"       \"Management of epilepsy and pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"       Folic acid",
"      </a>",
"      supplementation will not prevent all neural tube defects, such as those related to chromosomal abnormalities and other nonfolate-related mechanisms. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Treatment failures'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/1\">",
"      Sanderson P, McNulty H, Mastroiacovo P, et al. Folate bioavailability: UK Food Standards Agency workshop report. Br J Nutr 2003; 90:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/2\">",
"      Czeizel AE, Dud&aacute;s I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med 1992; 327:1832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/3\">",
"      Goh YI, Bollano E, Einarson TR, Koren G. Prenatal multivitamin supplementation and rates of congenital anomalies: a meta-analysis. J Obstet Gynaecol Can 2006; 28:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/4\">",
"      Milunsky A, Jick H, Jick SS, et al. Multivitamin/folic acid supplementation in early pregnancy reduces the prevalence of neural tube defects. JAMA 1989; 262:2847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/5\">",
"      Berry RJ, Li Z, Erickson JD, et al. Prevention of neural-tube defects with folic acid in China. China-U.S. Collaborative Project for Neural Tube Defect Prevention. N Engl J Med 1999; 341:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/6\">",
"      Shaw GM, Schaffer D, Velie EM, et al. Periconceptional vitamin use, dietary folate, and the occurrence of neural tube defects. Epidemiology 1995; 6:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/7\">",
"      Thompson SJ, Torres ME, Stevenson RE, et al. Periconceptional multivitamin folic acid use, dietary folate, total folate and risk of neural tube defects in South Carolina. Ann Epidemiol 2003; 13:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/8\">",
"      Czeizel AE, Dob&oacute; M, Vargha P. Hungarian cohort-controlled trial of periconceptional multivitamin supplementation shows a reduction in certain congenital abnormalities. Birth Defects Res A Clin Mol Teratol 2004; 70:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/9\">",
"      De-Regil LM, Fern&aacute;ndez-Gaxiola AC, Dowswell T, Pe&ntilde;a-Rosas JP. Effects and safety of periconceptional folate supplementation for preventing birth defects. Cochrane Database Syst Rev 2010; :CD007950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/10\">",
"      Hern&aacute;ndez-D&iacute;az S, Werler MM, Walker AM, Mitchell AA. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med 2000; 343:1608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/11\">",
"      Wald NJ, Hackshaw AD, Stone R, Sourial NA. Blood folic acid and vitamin B12 in relation to neural tube defects. Br J Obstet Gynaecol 1996; 103:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/12\">",
"      Adams MJ Jr, Khoury MJ, Scanlon KS, et al. Elevated midtrimester serum methylmalonic acid levels as a risk factor for neural tube defects. Teratology 1995; 51:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/13\">",
"      van der Put NM, van Straaten HW, Trijbels FJ, Blom HJ. Folate, homocysteine and neural tube defects: an overview. Exp Biol Med (Maywood) 2001; 226:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/14\">",
"      Steegers-Theunissen RP, Boers GH, Blom HJ, et al. Neural tube defects and elevated homocysteine levels in amniotic fluid. Am J Obstet Gynecol 1995; 172:1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/15\">",
"      Rothenberg SP, da Costa MP, Sequeira JM, et al. Autoantibodies against folate receptors in women with a pregnancy complicated by a neural-tube defect. N Engl J Med 2004; 350:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/16\">",
"      Molloy AM, Quadros EV, Sequeira JM, et al. Lack of association between folate-receptor autoantibodies and neural-tube defects. N Engl J Med 2009; 361:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/17\">",
"      Kirke PN, Mills JL, Molloy AM, et al. Impact of the MTHFR C677T polymorphism on risk of neural tube defects: case-control study. BMJ 2004; 328:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/18\">",
"      Whitehead AS, Gallagher P, Mills JL, et al. A genetic defect in 5,10 methylenetetrahydrofolate reductase in neural tube defects. QJM 1995; 88:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/19\">",
"      van der Put NM, Steegers-Theunissen RP, Frosst P, et al. Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida. Lancet 1995; 346:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/20\">",
"      van der Put NM, Eskes TK, Blom HJ. Is the common 677C--&gt;T mutation in the methylenetetrahydrofolate reductase gene a risk factor for neural tube defects? A meta-analysis. QJM 1997; 90:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/21\">",
"      Botto LD, Yang Q. 5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE review. Am J Epidemiol 2000; 151:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/22\">",
"      Cunha AL, Hirata MH, Kim CA, et al. Metabolic effects of C677T and A1298C mutations at the MTHFR gene in Brazilian children with neural tube defects. Clin Chim Acta 2002; 318:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/23\">",
"      Perez AB, D'Almeida V, Vergani N, et al. Methylenetetrahydrofolate reductase (MTHFR): incidence of mutations C677T and A1298C in Brazilian population and its correlation with plasma homocysteine levels in spina bifida. Am J Med Genet A 2003; 119A:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/24\">",
"      Barber R, Shalat S, Hendricks K, et al. Investigation of folate pathway gene polymorphisms and the incidence of neural tube defects in a Texas hispanic population. Mol Genet Metab 2000; 70:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/25\">",
"      Nurk E, Tell GS, Refsum H, et al. Associations between maternal methylenetetrahydrofolate reductase polymorphisms and adverse outcomes of pregnancy: the Hordaland Homocysteine Study. Am J Med 2004; 117:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/26\">",
"      Brody LC, Conley M, Cox C, et al. A polymorphism, R653Q, in the trifunctional enzyme methylenetetrahydrofolate dehydrogenase/methenyltetrahydrofolate cyclohydrolase/formyltetrahydrofolate synthetase is a maternal genetic risk factor for neural tube defects: report of the Birth Defects Research Group. Am J Hum Genet 2002; 71:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/27\">",
"      Parle-McDermott A, Pangilinan F, O'Brien KK, et al. A common variant in MTHFD1L is associated with neural tube defects and mRNA splicing efficiency. Hum Mutat 2009; 30:1650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/28\">",
"      Shaw GM, Lu W, Zhu H, et al. 118 SNPs of folate-related genes and risks of spina bifida and conotruncal heart defects. BMC Med Genet 2009; 10:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/29\">",
"      Parle-McDermott A, Kirke PN, Mills JL, et al. Confirmation of the R653Q polymorphism of the trifunctional C1-synthase enzyme as a maternal risk for neural tube defects in the Irish population. Eur J Hum Genet 2006; 14:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/30\">",
"      De Marco P, Merello E, Calevo MG, et al. Evaluation of a methylenetetrahydrofolate-dehydrogenase 1958G&gt;A polymorphism for neural tube defect risk. J Hum Genet 2006; 51:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/31\">",
"      ACOG Committee on Practice Bulletins. ACOG practice bulletin. Clinical management guidelines for obstetrician-gynecologists. Number 44, July 2003. (Replaces Committee Opinion Number 252, March 2001). Obstet Gynecol 2003; 102:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/32\">",
"      Wilson RD, Davies G, D&eacute;silets V, et al. The use of folic acid for the prevention of neural tube defects and other congenital anomalies. J Obstet Gynaecol Can 2003; 25:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/33\">",
"      Centers for Disease Control (CDC). Use of folic acid for prevention of spina bifida and other neural tube defects--1983-1991. MMWR Morb Mortal Wkly Rep 1991; 40:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/34\">",
"      Folic acid for the prevention of neural tube defects. American Academy of Pediatrics. Committee on Genetics. Pediatrics 1999; 104:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/35\">",
"      Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. MRC Vitamin Study Research Group. Lancet 1991; 338:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/36\">",
"      Wald NJ, Law MR, Morris JK, Wald DS. Quantifying the effect of folic acid. Lancet 2001; 358:2069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/37\">",
"      Wald NJ. Folic acid and the prevention of neural-tube defects. N Engl J Med 2004; 350:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/38\">",
"      Kennedy D, Koren G. Identifying women who might benefit from higher doses of folic acid in pregnancy. Can Fam Physician 2012; 58:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/39\">",
"      Oyama K, Sugimura Y, Murase T, et al. Folic acid prevents congenital malformations in the offspring of diabetic mice. Endocr J 2009; 56:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/40\">",
"      Wilson RD, Johnson JA, Wyatt P, et al. Pre-conceptional vitamin/folic acid supplementation 2007: the use of folic acid in combination with a multivitamin supplement for the prevention of neural tube defects and other congenital anomalies. J Obstet Gynaecol Can 2007; 29:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/41\">",
"      Alaimo K, McDowell MA, Briefel RR, et al. Dietary intake of vitamins, minerals, and fiber of persons ages 2 months and over in the United States: Third National Health and Nutrition Examination Survey, Phase 1, 1988-91. Adv Data 1994; :1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/42\">",
"      Tamura T, Picciano MF. Folate and human reproduction. Am J Clin Nutr 2006; 83:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/43\">",
"      Centers for Disease Control and Prevention (CDC). Use of supplements containing folic acid among women of childbearing age--United States, 2007. MMWR Morb Mortal Wkly Rep 2008; 57:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/44\">",
"      Laurence KM. Fetal malformations and abnormalities. Lancet 1974; 2:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/45\">",
"      Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects. MMWR Recomm Rep 1992; 41(RR-14):1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/46\">",
"      U.S. Preventive Services Task Force. Folic acid for the prevention of neural tube defects: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009; 150:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/47\">",
"      Wolff T, Witkop CT, Miller T, et al. Folic acid supplementation for the prevention of neural tube defects: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2009; 150:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/48\">",
"      Grimes DA. Unplanned pregnancies in the United States. Obstet Gynecol 1986; 67:438.",
"     </a>",
"    </li>",
"    <li>",
"     www.aafp.org/online/en/home/clinical/exam.html.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/50\">",
"      Centers for Disease Control and Prevention (CDC). Use of dietary supplements containing folic acid among women of childbearing age--United States, 2005. MMWR Morb Mortal Wkly Rep 2005; 54:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/51\">",
"      Locksmith GJ, Duff P. Preventing neural tube defects: the importance of periconceptional folic acid supplements. Obstet Gynecol 1998; 91:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/52\">",
"      Gunter EW, Bowman BA, Caudill SP, et al. Results of an international round robin for serum and whole-blood folate. Clin Chem 1996; 42:1689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/53\">",
"      Rosano A, Smithells D, Cacciani L, et al. Time trends in neural tube defects prevalence in relation to preventive strategies: an international study. J Epidemiol Community Health 1999; 53:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/54\">",
"      Ray JG, Singh G, Burrows RF. Evidence for suboptimal use of periconceptional folic acid supplements globally. BJOG 2004; 111:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/55\">",
"      Standards of Identity For Enriched Grain Products to Require Addition of Folic Acid. Federal Register. March 5, 1996; 61:8781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/56\">",
"      Brent RL, Oakley GP Jr. The Food and Drug Administration must require the addition of more folic acid in \"enriched\" flour and other grains. Pediatrics 2005; 116:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/57\">",
"      Daly LE, Kirke PN, Molloy A, et al. Folate levels and neural tube defects. Implications for prevention. JAMA 1995; 274:1698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/58\">",
"      Mosley BS, Cleves MA, Siega-Riz AM, et al. Neural tube defects and maternal folate intake among pregnancies conceived after folic acid fortification in the United States. Am J Epidemiol 2009; 169:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/59\">",
"      Honein MA, Paulozzi LJ, Mathews TJ, et al. Impact of folic acid fortification of the US food supply on the occurrence of neural tube defects. JAMA 2001; 285:2981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/60\">",
"      Centers for Disease Control and Prevention (CDC). Racial/ethnic differences in the birth prevalence of spina bifida - United States, 1995-2005. MMWR Morb Mortal Wkly Rep 2009; 57:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/61\">",
"      De Wals P, Tairou F, Van Allen MI, et al. Reduction in neural-tube defects after folic acid fortification in Canada. N Engl J Med 2007; 357:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/62\">",
"      Castilla EE, Orioli IM, Lopez-Camelo JS, et al. Preliminary data on changes in neural tube defect prevalence rates after folic acid fortification in South America. Am J Med Genet A 2003; 123A:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/63\">",
"      L&oacute;pez-Camelo JS, Orioli IM, da Gra&ccedil;a Dutra M, et al. Reduction of birth prevalence rates of neural tube defects after folic acid fortification in Chile. Am J Med Genet A 2005; 135:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/64\">",
"      Evans MI, Llurba E, Landsberger EJ, et al. Impact of folic acid fortification in the United States: markedly diminished high maternal serum alpha-fetoprotein values. Obstet Gynecol 2004; 103:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/65\">",
"      Taylor TN, Farkouh RA, Graham JB, et al. Potential reduction in neural tube defects associated with use of Metafolin-fortified oral contraceptives in the United States. Am J Obstet Gynecol 2011; 205:460.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/66\">",
"      Charles D, Ness AR, Campbell D, et al. Taking folate in pregnancy and risk of maternal breast cancer. BMJ 2004; 329:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/67\">",
"      Oakley GP, Mandel JS. Folic acid fortification remains an urgent health priority. BMJ 2004; 329:1376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/68\">",
"      Zhang S, Hunter DJ, Hankinson SE, et al. A prospective study of folate intake and the risk of breast cancer. JAMA 1999; 281:1632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/69\">",
"      Zhang SM, Willett WC, Selhub J, et al. Plasma folate, vitamin B6, vitamin B12, homocysteine, and risk of breast cancer. J Natl Cancer Inst 2003; 95:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/70\">",
"      Shrubsole MJ, Jin F, Dai Q, et al. Dietary folate intake and breast cancer risk: results from the Shanghai Breast Cancer Study. Cancer Res 2001; 61:7136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/61/5081/abstract/71\">",
"      Mills JL, Carter TC. Invited commentary: Preventing neural tube defects and more via food fortification? Am J Epidemiol 2009; 169:18.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 423 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.1.191.153-863D5741FF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_61_5081=[""].join("\n");
var outline_f4_61_5081=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      FOLATE AND FOLIC ACID",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Genetic etiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - MTHFR polymorphisms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - MTHFD1 polymorphisms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      FOLIC ACID SUPPLEMENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      High risk women",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Previously affected pregnancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Anticonvulsant therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H106393937\">",
"      - Other conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Primary prevention in low risk women",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Folic acid supplements",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Food fortification",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H183508197\">",
"      - Fortified oral contraceptives",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Risks of folic acid supplementation during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Treatment failures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Possible additional benefits",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/423\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/423|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/58/7085\" title=\"table 1\">",
"      Selected food sources of folate and folic acid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/33/23068\" title=\"table 2\">",
"      Recurrence risk NTDs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/0/5130?source=related_link\">",
"      Diagnosis and treatment of vitamin B12 and folate deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/16/15625?source=related_link\">",
"      Management of epilepsy and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/44/28362?source=related_link\">",
"      Nutrition in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/37/19034?source=related_link\">",
"      Overview of homocysteine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/15/6387?source=related_link\">",
"      Patient information: Vitamin B12 deficiency and folate (folic acid) deficiency (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/35/25145?source=related_link\">",
"      Prenatal screening and diagnosis of neural tube defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22633?source=related_link\">",
"      Risks associated with epilepsy and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/46/40682?source=related_link\">",
"      Twin pregnancy: Prenatal issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36586?source=related_link\">",
"      Vitamin supplementation in disease prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_61_5082="Duodenal ulcer with visible vessel";
var content_f4_61_5082=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F54960%7EGAST%2F79058%7EGAST%2F61604&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F54960%7EGAST%2F79058%7EGAST%2F61604&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Duodenal ulcer with visible vessel",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 450px; height: 385px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Upper endoscopy showing a duodenal ulcer with a nonbleeding visible vessel in a large circumferential ulcer&nbsp;(Forrest classification IIa).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rome Jutabha.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    Duodenal ulcer with visible vessel",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 254px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Duodenal ulcer in a patient with recent upper gastrointestinal bleeding. The ulcer base (arrows) is visible as the whitish rim underlying the protruding vessel. The erythematous mound in the center of the ulcer represents an arteriole that has eroded into the lumen of the duodenum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Eric D Libby, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gastric ulcer with a visible vessel",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 318px; height: 322px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ulcer in the gastric antrum seen on endoscopy. The visible vessel appears as a small protuberance in the one o'clock position.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Eric D Libby, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_61_5082=[""].join("\n");
var outline_f4_61_5082=null;
var title_f4_61_5083="Causes of benign PSA elevation";
var content_f4_61_5083=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F79754&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F79754&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Benign causes for an elevated PSA",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Benign prostatic hyperplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute prostatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Subclinical inflammation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prostate biopsy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cystoscopy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TURP",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urinary retention",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ejaculation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Digital rectal examination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Perineal trauma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prostatic infarction",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_61_5083=[""].join("\n");
var outline_f4_61_5083=null;
var title_f4_61_5084="Adverse effects of methotrexate";
var content_f4_61_5084=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F80229&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F80229&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Major adverse effects of methotrexate*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Bone marrow toxicity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neutropenia (most common, usually reversible)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thrombocytopenia (dose related, usually reversible)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anemia (rare)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Hepatic toxicity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cirrhosis &amp; fibrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Pulmonary toxicity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Opportunistic infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        PCP, CMV, Herpes zoster, fungal, mycobacterial, etc",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Noninfectious conditions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hypersensitivity pneumonitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Organizing pneumonia (previously called bronchiolitis obliterans with organizing pneumonia or BOOP)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Acute lung injury (noncardiogenic pulmonary edema)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Pulmonary fibrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Asthma/hyperreactive airways disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Pleuritis and/or pleural effusion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Miscellaneous",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oligospermia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Teratogenicity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malignancy",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PCP: Pneumocystis pneumonia; CMV: cytomegalovirus.",
"     <br/>",
"     * Major adverse effects are defined as potentially life-threatening (incidence &lt;1 percent) or requiring withdrawal of treatment (incidence 3 to 15 percent).",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_61_5084=[""].join("\n");
var outline_f4_61_5084=null;
var title_f4_61_5085="Breast cancer specific survival according to stage at diagnosis";
var content_f4_61_5085=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F78108&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F78108&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Breast cancer specific survival according to stage at diagnosis and lymph node status; SEER database, 1988-2000",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"3\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"5\" rowspan=\"1\">",
"        Cancer specific survival, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"5\" rowspan=\"1\">",
"        Stage of disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3\">",
"        I",
"       </td>",
"       <td class=\"subtitle3\">",
"        IIA",
"       </td>",
"       <td class=\"subtitle3\">",
"        IIB",
"       </td>",
"       <td class=\"subtitle3\">",
"        IIIA",
"       </td>",
"       <td class=\"subtitle3\">",
"        IIIB",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\" rowspan=\"1\">",
"        Number of lymph nodes examined",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0",
"       </td>",
"       <td>",
"        92",
"       </td>",
"       <td>",
"        82",
"       </td>",
"       <td>",
"        71",
"       </td>",
"       <td>",
"        58",
"       </td>",
"       <td>",
"        49",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1 to 3",
"       </td>",
"       <td>",
"        98",
"       </td>",
"       <td>",
"        93",
"       </td>",
"       <td>",
"        81",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        65",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4 to 6",
"       </td>",
"       <td>",
"        96",
"       </td>",
"       <td>",
"        91",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        71",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        7 to 9",
"       </td>",
"       <td>",
"        96",
"       </td>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        81",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        71",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        10 to 14",
"       </td>",
"       <td>",
"        96",
"       </td>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        82",
"       </td>",
"       <td>",
"        71",
"       </td>",
"       <td>",
"        72",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        15 to 19",
"       </td>",
"       <td>",
"        96",
"       </td>",
"       <td>",
"        89",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        71",
"       </td>",
"       <td>",
"        69",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        20+",
"       </td>",
"       <td>",
"        95",
"       </td>",
"       <td>",
"        88",
"       </td>",
"       <td>",
"        78",
"       </td>",
"       <td>",
"        68",
"       </td>",
"       <td>",
"        67",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\" rowspan=\"1\">",
"        Ratio of positive to total number of lymph nodes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0.01 to 0.25",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        92",
"       </td>",
"       <td>",
"        85",
"       </td>",
"       <td>",
"        81",
"       </td>",
"       <td>",
"        78",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0.26 to 0.5",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        85",
"       </td>",
"       <td>",
"        78",
"       </td>",
"       <td>",
"        73",
"       </td>",
"       <td>",
"        76",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0.51 to 0.75",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        77",
"       </td>",
"       <td>",
"        71",
"       </td>",
"       <td>",
"        67",
"       </td>",
"       <td>",
"        63",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0.76 to 1.00",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        61",
"       </td>",
"       <td>",
"        55",
"       </td>",
"       <td>",
"        50",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     SEER: Surveillance, Epidemiology, and End Results Database of the National Cancer Institute.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Joslyn SA, et al. Breast Cancer Res Treat 2005; 91:11.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_61_5085=[""].join("\n");
var outline_f4_61_5085=null;
var title_f4_61_5086="Steroid hormone action";
var content_f4_61_5086=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F56745&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F56745&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Steroid hormone action",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 404px; height: 310px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic model for the mechanism of action of steroid hormones, such as cortisol, aldosterone, and calcitriol. The hormone enters the cell by diffusion and combines with a specific receptor in the cytosol. The active hormone-receptor complex, which unmasks the DNA binding site on the receptor, then migrates to the nucleus where it interacts with specific genes, leading to RNA transcription and the eventual production of new proteins that are responsible for the physiologic actions of the hormone.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Rose, BD, Clinical Physiology of Acid-Base and Electrolyte Disorders, 4th ed, McGraw-Hill, New York, 1994.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_61_5086=[""].join("\n");
var outline_f4_61_5086=null;
var title_f4_61_5087="Plain radiograph of an infant with duodenal atresia";
var content_f4_61_5087=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F73385&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F73385&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Plain radiograph of an infant with duodenal atresia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 318px; height: 319px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note the double bubble caused by dilation of the stomach and proximal duodenum; distal gas is absent.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_61_5087=[""].join("\n");
var outline_f4_61_5087=null;
